Psychedelics and psychosis: Quantifying the risk

Just over a year ago, I somewhat reluctantly weighed in on the implications for psychiatry of the resurgent interest in psychedelic drugs (Price, 2024). In contrast to the “psychedelic era” of the 1960s and 1970s, this time public interest in these compounds has been accompanied by skillful politico‐legal advocacy and systematic research. Both of those endeavors require high levels of funding, and both private philanthropic and for‐profit pharmaceutical entities have, for better or worse, stepped in.